首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1461510

全球生物製药市场规模、份额、成长分析、按产品类型、按应用、按最终用途 - 行业预测，2024-2031 年

Global Biopharmaceuticals Market Size, Share, Growth Analysis, By By Product type(Monoclonal Antibodies, Gene Therapies), By Application(Oncology, Inflammatory Diseases), By End-use(Health And Care, Biopharma Companies) - Industry Forecast 2024-2031

出版日期: 2024年04月05日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球生物製药市场价值约3.7787亿美元，较2023年的4.0734亿美元有所增长，预测期内（2024-2031年）复合年增长率为7.80%，预计到年终将达到7.4287亿美元。 2031.

生物製药公司向其他生物製药公司提供包装和药物製造等合约服务，使大型生物製药公司能够简化製造流程并专注于药物发现和行销。由于内部生产能力有限，较小的生物技术公司通常将填充和成品製造外包，这有助于减少资本支出。源自生物技术的生物製药利用直接从生物来源（主要是活生物体，包括被称为基因改造生物的基因改造动物和植物）提取的蛋白质和核酸，这仍然存在争议和实验性。核准的生物製药中值得注意的是重组人类胰岛素，目前市面上有近300种产品。市场成长是由人口老化、医疗保健意识提高和医疗成本上升等因素推动的，而新生物製药的持续研发和核准预计将进一步推动市场扩张。然而，该行业面临重大挑战，特别是这些药物的高成本，需要大幅降低成本以确保业务永续性。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2021年）
主要市场参与者所采取的策略
关键成功策略
近期市集活动
主要企业市场占有率（2021年）

主要企业简介

Pfizer, Inc.
F. Hoffmann-La Roche AG
Johnson & Johnson Services, Inc.
Sanofi
Amgen Inc.
AbbVie Inc.
Merck & Co., Inc.
Biogen Idec
Bayer AG
Eli Lilly and Company
Novartis AG

简介目录

Product Code: SQMIG35H2058

Global Biopharmaceuticals Market was valued around USD 377.87 million in 2022 and is expected to rise from USD 407.34 million in 2023 to reach USD 742.87 million by the end of 2031, by recording a CAGR of 7.80% during the forecast period (2024-2031).

A biopharmaceutical company offers contract services to other biopharmaceutical firms, encompassing packaging and drug manufacturing, thereby allowing larger biopharmaceutical entities to streamline their manufacturing processes and focus on drug discovery and marketing. Small biotechnology companies often outsource fill and finish manufacturing due to limited in-house production capacity, aiding in reducing capital expenditures. Biopharmaceuticals, derived from biotechnology, utilize proteins and nucleic acids extracted directly from biological sources, primarily living organisms including genetically modified plants and animals known as transgenic organisms, although this method remains contentious and experimental. Notable among approved biopharmaceuticals is recombinant human insulin, with nearly 300 such products currently available. Market growth is driven by factors such as an aging population, increased healthcare awareness, and rising healthcare costs, with ongoing research and development and approval for newer biopharmaceutical products expected to further propel market expansion. Nevertheless, the industry faces significant challenges, notably the high cost of these drugs, necessitating substantial reduction to ensure business sustainability.

Top-down and bottom-up approaches were used to estimate and validate the size of the global biopharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biopharmaceuticals Market Segmental Analysis

The global biopharmaceuticals market is segmented on the basis of product type, application, end use, and region. With respect to segmentation by product type, the market is segmented into the Monoclonal Antibodies, Gene Therapies, Thrombolytics and Anticoagulants, and Recombinant Protein. Based on classification by application, the market is categorized into Oncology, Inflammatory Diseases, Cardiology, Neurology, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, and Others. With respect to categorization by end use, the market is grouped into Health and Care, Biopharma Companies, Diagnostic Labs, Clinical Research Institute, Clinical Research Organizations (CROs), and Others. Region wise, the market is widespread into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

Drivers of the Global Biopharmaceuticals Market

Globally, chronic illnesses like cancer, diabetes, and heart disease pose significant threats to health and well-being, with the World Health Organization projecting cancer to be responsible for nearly one-sixth of all deaths by 2020. Biopharmaceuticals leveraging protein-based therapies have emerged as effective treatments for various cancers, yet challenges persist due to factors such as increased tobacco usage, unhealthy dietary habits, excessive alcohol consumption, and sedentary lifestyles. Cardiovascular disease, a leading cause of mortality, claims lives every second in the United States alone, spurring innovation in the field, exemplified by companies like Invizius and 3P Biopharmaceuticals developing groundbreaking technologies to aid cardiovascular patients undergoing hemodialysis. With the prevalence of chronic diseases on the rise globally, the biopharmaceutical market is poised for significant expansion between 2024 and 2031.

Restraints in the Global Biopharmaceuticals Market

Due to the combination of low incomes and the heavy burden of healthcare expenses, individuals in developing nations face significant barriers in affording biomedicines and therapies, potentially hindering market expansion in the foreseeable future. According to the United Nations Development Program, as of 2020, 1.3 billion people, equivalent to 22% of the global population, live in poverty, limiting their access to adequate healthcare services due to financial constraints. Additionally, lacking robust healthcare infrastructure, half of the world's population is unable to avail themselves of essential medical facilities, as reported by the World Health Organization. These challenges collectively impact the biopharmaceuticals market, posing considerable difficulties for its growth trajectory.

Market Trends of the Global Biopharmaceuticals Market

The rapid growth of the biopharmaceuticals market is predominantly fueled by the effective utilization of monoclonal antibodies and their derivatives in therapeutic treatments. Various ailments such as cancer, rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases have benefited from these antibodies' therapeutic potential. The global healthcare systems have been under immense pressure due to the COVID-19 pandemic, prompting relentless efforts from researchers worldwide to address this escalating challenge. Consequently, there's an anticipated surge in demand for COVID-19-specific monoclonal antibodies to mitigate the impact of the pandemic.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Biopharmaceuticals Market by By Product type

Market Overview
Monoclonal Antibodies
Gene Therapies
Thrombolytics and Anticoagulants
Recombinant Protein.

Global Biopharmaceuticals Market by Application

Market Overview
Oncology
Inflammatory Diseases
Cardiology
Neurology
Autoimmune Disorders
Metabolic Disorders
Hormonal Disorders
and Others

Global Biopharmaceuticals Market by End-use

Market Overview
Health And Care
Biopharma Companies
Diagnostic Labs
Clinical Research Institute
Clinical Research Organizations (CROs)
and Others

Global Biopharmaceuticals Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Pfizer, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Idec
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments